2019 American Transplant Congress
Epstein Barr Virus DNA Integration in B Cell Lymphomas of Post-Transplant Lymphoproliferative Disorder
Surgery, Division of Abdominal Transplant, Stanford University School of Medicine, Stanford, CA
*Purpose: Epstein Barr virus-positive (EBV+) B cell lymphomas can arise in immunosuppressed individuals, such as organ transplant recipients in the context of post-transplant lymphoproliferative disorder…2019 American Transplant Congress
Post-transplant Lymphoproliferative Disorder Following Intestine Transplantation: Contemporary Single Center Experience
Georgetown Transplant Institute, MedStar Georgetown University Hospital, Washington, DC
*Purpose: The purpose of this study was to examine the characteristics and risk factors for PTLD after intestinal transplant.*Methods: Retrospective review of intestinal transplant recipients…2019 American Transplant Congress
EBV+ PTLD in the Modern Immunosuppression Era: Role of EBV Serology and DNAemia-Preliminary Data from CTOT-C06
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOT-C)-06 is an…2019 American Transplant Congress
Lower Rates of Epstein-Barr Virus Viremia and Post-Transplant Lymphoproliferative Disease in Pediatric Solid Organ Transplant Recipients Who Received Valganciclovir Prophylaxis
*Purpose: Antiviral prophylaxis to prevent post-transplant lymphoproliferative disease (PTLD) remains controversial, but some data suggest that valganciclovir or ganciclovir use in Epstein-Barr virus (EBV) high-risk…2019 American Transplant Congress
Regulation of Host microRNA Expression by Natural Variants of Epstein Barr Virus (EBV) Latent Membrane Protein 1 (LMP1)
*Purpose: Malignancies attributable to EBV, such as post-transplant lymphoproliferative disorder (PTLD), represent 1.8% of global cancer deaths. PTLD occurs in 1-20% of transplant recipients and…2019 American Transplant Congress
Mass Cytometry-Based Characterization of Adaptive Immunity in Transplant Recipients with Self-Limiting or Chronic EBV Viremia
1UHN, Toronto, ON, Canada, 2SickKids Research Inst, Toronto, ON, Canada
*Purpose: SOT recipients are at high risk for EBV-associated PTLD. EBV viremia is a risk factor for PTLD. In some patients viremia is self-limited while…2019 American Transplant Congress
Ex-Vivo Perfusion Mediated Delivery of Rituximab to Clear Latent Epstein-Barr Virus
*Purpose: Post-transplant lymphoproliferative disorder (PTLD) can manifest as a B-cell malignancy associated with Epstein-Barr virus (EBV) infection. Risk of PTLD is greatest in EBV D+/R-…2018 American Transplant Congress
Incidence of Epstein Barr Virus (EBV) DNAemia in EBV-Seronegative Solid Organ Transplant (SOT) Recipients with EBV-Seropositive Donors
Purpose: Since 2002, a pre-emptive approach to post-transplant lymhoproliferative disease prevention has been used at our center that includes EBV viral load (VL) monitoring in…2018 American Transplant Congress
Prospective Analysis of EBV+ PTLD Incidence in Pediatric Transplant Recipients in the Modern Era
Post-transplant lymphoproliferative disorder (PTLD) remains a serious problem in the pediatric transplant population. The Clinical Trials of Organ Transplantation in Children (CTOTC)-06 is an NIAID-sponsored…2018 American Transplant Congress
Programmed Cell Death Ligand 1 (PD-L1) Expression is Associated with Subtypes of Post-Transplant Lymphoproliferative Disorders (PTLD)
Introduction: PD-L1 expression on select tumor cells engages the PD-1 receptor on T cells, inhibiting anti-tumor immune responses. PD-L1 has been detected in cases of…
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- 6
- …
- 9
- Next Page »